You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 9, 2024

~ Buy the TAZVERIK (tazemetostat hydrobromide) Drug Profile, 2024 PDF Report in the Report Store ~

TAZVERIK Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Tazverik, and when can generic versions of Tazverik launch?

Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-two patents protecting this drug.

This drug has three hundred and eighty-five patent family members in thirty-nine countries.

The generic ingredient in TAZVERIK is tazemetostat hydrobromide. One supplier is listed for this compound. Additional details are available on the tazemetostat hydrobromide profile page.

DrugPatentWatch® Generic Entry Outlook for Tazverik

Tazverik was eligible for patent challenges on January 23, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 19, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TAZVERIK?
  • What are the global sales for TAZVERIK?
  • What is Average Wholesale Price for TAZVERIK?
Summary for TAZVERIK
International Patents:385
US Patents:22
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 90
Clinical Trials: 15
Patent Applications: 301
Drug Prices: Drug price information for TAZVERIK
What excipients (inactive ingredients) are in TAZVERIK?TAZVERIK excipients list
DailyMed Link:TAZVERIK at DailyMed
Drug patent expirations by year for TAZVERIK
Drug Prices for TAZVERIK

See drug prices for TAZVERIK

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TAZVERIK
Generic Entry Date for TAZVERIK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAZVERIK

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Weill Medical College of Cornell UniversityPhase 2
Genentech, Inc.Phase 2
Applebaum FoundationPhase 1

See all TAZVERIK clinical trials

US Patents and Regulatory Information for TAZVERIK

TAZVERIK is protected by thirty-eight US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAZVERIK is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TAZVERIK

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2

Method for treating cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Method for treating cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Method for treating cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Method for treating cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Inhibitors of human EZH2 and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Inhibitors of human EZH2 and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Aryl- or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Methods of treating cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Aryl-or heteroaryl-substituted benzene compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Method for treating cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA

Method for treating cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION

Method for treating cancer
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Inhibitors of human EZH2, and methods of use thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2

FDA Regulatory Exclusivity protecting TAZVERIK

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: ⤷  Sign Up

INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TAZVERIK

When does loss-of-exclusivity occur for TAZVERIK?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 15350108
Patent: Method for treating cancer
Estimated Expiration: ⤷  Sign Up

Patent: 21204706
Patent: METHOD FOR TREATING CANCER
Estimated Expiration: ⤷  Sign Up

Patent: 24201171
Patent: METHOD FOR TREATING CANCER
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2017010166
Patent: método de tratamento de um tumor sólido, método de inibição da atividade, forma de dosagem oral para o tratamento de um tumor sólido, formulação farmacêutica sólida, processo para a preparação de uma formulação farmacêutica, e, composição farmacêutica sólida
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 67664
Patent: FORMULATIONS PHARMACEUTIQUES COMPRENANT DES INHIBITEURS DE L'HISTONE METHYLTRANSFERASE EZH2 HUMAIN (PHARMACEUTICAL FORMULATIONS COMPRISING INHIBITORS OF HUMAN HISTONE METHYLTRANSFERASE EZH2)
Estimated Expiration: ⤷  Sign Up

China

Patent: 7249591
Patent: 治疗癌症的方法 (Method for treating cancer)
Estimated Expiration: ⤷  Sign Up

Patent: 6650500
Patent: 治疗癌症的方法 (Methods of treating cancer)
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 20916
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 1791095
Patent: СПОСОБ ЛЕЧЕНИЯ РАКА
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 20916
Patent: MÉTHODE DE TRAITEMENT DU CANCER (METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷  Sign Up

Patent: 72742
Patent: EPZ-6438 POUR UTILISATION DANS UNE MÉTHODE DE TRAITEMENT DU CANCER (EPZ-6438 FOR USE IN A METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷  Sign Up

Finland

Patent: 20916
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 62159
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 2182
Patent: שיטות לטיפול בסרטן (Method for treating cancer)
Estimated Expiration: ⤷  Sign Up

Patent: 6080
Patent: שיטות לטיפול בסרטן (Method for treating cancer)
Estimated Expiration: ⤷  Sign Up

Patent: 4252
Patent: שיטות לטיפול בסרטן (Method for treating cancer)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 29684
Estimated Expiration: ⤷  Sign Up

Patent: 85810
Estimated Expiration: ⤷  Sign Up

Patent: 17537899
Patent: 癌を処置する方法
Estimated Expiration: ⤷  Sign Up

Patent: 21073241
Patent: 癌を処置する方法 (METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷  Sign Up

Patent: 23062189
Patent: 癌を処置する方法
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 20916
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 17006089
Patent: METODO PARA TRATAR EL CANCER. (METHOD FOR TREATING CANCER.)
Estimated Expiration: ⤷  Sign Up

Patent: 21006734
Patent: METODO PARA TRATAR EL CANCER. (METHOD FOR TREATING CANCER.)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 1696
Patent: Method for treating cancer
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 20916
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 20916
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201703806X
Patent: METHOD FOR TREATING CANCER
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 20916
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2338802
Estimated Expiration: ⤷  Sign Up

Patent: 2644844
Estimated Expiration: ⤷  Sign Up

Patent: 170103768
Patent: 암을 치료하기 위한 방법 (METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷  Sign Up

Patent: 210156840
Patent: 암을 치료하기 위한 방법 (METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷  Sign Up

Patent: 240035908
Patent: 암을 치료하기 위한 방법 (METHOD FOR TREATING CANCER)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 47819
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAZVERIK around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2906537 COMPOSÉS DE BENZÈNE SUBSTITUÉ (SUBSTITUTED BENZENE COMPOUNDS) ⤷  Sign Up
China 105797158 人EZH2抑制剂及其应用方法 (Inhibitors of human EZH2, and methods of use thereof) ⤷  Sign Up
Singapore 10201608577R SALT FORM OF A HUMAN HI STONE METHYLTRANSF ERASE EZH2 INHIBITOR ⤷  Sign Up
Japan 2018087239 置換ベンゼン化合物 (SUBSTITUTED BENZENE COMPOUNDS) ⤷  Sign Up
Hungary E046790 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.